Occult hepatitis B: the masked driver of portal hypertension and life-threatening variceal hemorrhage Authors: Prabhat Kaphle, Raj Kumar Koirala, Maya Upadhyaya, Supriya Karna, Dhanlaxmi Giri, Pukar Gupta, Nabin Pahari, Liladhar Ojha, Suman Bhatta, Rohit Bhatt Published: 2026 ABSTRACT Introduction and importance:Occult hepatitis B infection (OBI), characterized by undetectable hepatitis B surface antigen (HBsAg) but detectable HBV DNA, is an underrecognized contributor to chronic liver injury and portal hypertension. Portal hypertension (PHT) commonly complicates chronic liver disease, often in the setting of cirrhosis, and can lead to life-threatening variceal hemorrhage without typical biochemical or imaging abnormalities.Case Presentation:We report a case of a 30-year-old Bangladeshi male with acute upper gastrointestinal bleeding and esophageal varices in the setting of occult HBV infection. The patient lacked classical risk factors for hepatitis B, and initial viral serology was negative for HBsAg and anti-HBc. However, HBV DNA testing later confirmed occult infection. Liver ultrasound was unremarkable, showing no signs of cirrhosis or focal lesions. The patient was managed successfully with supportive care, propranolol, and multiple sessions of EVL. Acute bleeding was controlled by blood transfusion and intravenous fluid resuscitation. Endoscopic variceal ligation sessions were performed to prevent rebleeding. During follow-up, varices remained stable without further bleeding. The patient is under ongoing surveillance for portal hypertension complications.Conclusion:OBI is a hidden cause of portal hypertension and variceal bleeding. HBV DNA testing is essential in patients with portal hypertension and negative serology. Prompt EVL and vigilant follow-up are critical to preventing fatal outcomes. Introduction Hepatitis B virus (HBV) infection is a leading cause of chronic liver disease worldwide, with nearly 2 billion people showing past or present serologic evidence of infection[1]. Occult hepatitis B virus (HBV) infection, or OBI, is characterized by the detection of HBV DNA in the blood or liver tissue despite the absence of detectable hepatitis B surface antigen (HBsAg) in the serum[2]. This occult form can lead to subtle but progressive liver damage, resulting in liver fibrosis, portal hypertension, cirrhosis, and hepatocellular carcinoma (HCC), even in the absence of overt serological or imaging findings[1,3].HIGHLIGHTOccult hepatitis B virus infection can silently drive portal hypertension, leading to esophageal varices and variceal hemorrhage.Classical HBV serologic markers may be negative, but HBV DNA testing can confirm the diagnosis.Endoscopic variceal ligation effectively controls life-threatening variceal bleeding, even without detectable HBsAg or cirrhosis on imaging. HIGHLIGHT Occult hepatitis B virus infection can silently drive portal hypertension, leading to esophageal varices and variceal hemorrhage. Occult hepatitis B virus infection can silently drive portal hypertension, leading to esophageal varices and variceal hemorrhage. Classical HBV serologic markers may be negative, but HBV DNA testing can confirm the diagnosis. Classical HBV serologic markers may be negative, but HBV DNA testing can confirm the diagnosis. Endoscopic variceal ligation effectively controls life-threatening variceal bleeding, even without detectable HBsAg or cirrhosis on imaging. Endoscopic variceal ligation effectively controls life-threatening variceal bleeding, even without detectable HBsAg or cirrhosis on imaging. Portal hypertension is a hemodynamic syndrome characterized by elevated pressure within the portal venous system. It primarily results from increased intrahepatic resistance to portal blood flow, most commonly due to cirrhosis[4,5]. Complications include gastroesophageal varices, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and HCC[5]. Recognizing occult HBV infection as an etiological factor in portal hypertension is critical, particularly in patients presenting with variceal hemorrhage without cirrhosis or classic HBV markers. Here, we present a case of OBI-associated portal hypertension with life-threatening variceal bleeding, despite normal liver imaging and negative classical HBV markers, which is recorded in compliance with CARE guidelines. Case history/examination A 30-year-old Bangladeshi male with no history of liver disease or comorbidities presented with two episodes of hematemesis and two episodes of melena within 24 hours prior to admission. He denied any risk factors, such as blood transfusions, intravenous drug use, tattoos, high-risk sexual behavior, or alcohol consumption. There was no family history of liver disease. On examination, the patient appeared acutely ill and pale but had no jaundice, clubbing, or lymphadenopathy. He was hypotensive, with a blood pressure of 80/60 mmHg and a pulse rate of 90 beats per minute; he was afebrile. Abdominal examination revealed no hepatomegaly, splenomegaly, or ascites, and cardiovascular and respiratory examinations were unremarkable. No clinical stigmata of chronic liver disease, such as spider nevi, palmar erythema, or asterixis, were observed. Investigations and treatment At presentation, the patient had low hemoglobin levels, and the results of other investigations are summarized in Table 1. Table 1Initial laboratory investigations.TestResultReference rangeHemoglobin7.8 g/dL13.5–17.5 g/dLPlatelets250 000/mm3150 000–450 000/mm3Prothrombin time13 sec11–15 secALT (alanine aminotransferase)65 IU/L7–56 IU/LAST (aspartate aminotransferase)50 IU/L10–40 IU/LTotal bilirubin1.4 mg/dL0.1–1.2 mg/dLSerum creatinine1.1 mg/dL0.7–1.3 mg/dLRandom blood sugar5.2 mmol/L4.0–6.0 mmol/LUrinalysis6–8 pus cells/HPF<5 pus cells/HPFViral serology initiallyHBsAg negative, HIV negative- Table 1Initial laboratory investigations.TestResultReference rangeHemoglobin7.8 g/dL13.5–17.5 g/dLPlatelets250 000/mm3150 000–450 000/mm3Prothrombin time13 sec11–15 secALT (alanine aminotransferase)65 IU/L7–56 IU/LAST (aspartate aminotransferase)50 IU/L10–40 IU/LTotal bilirubin1.4 mg/dL0.1–1.2 mg/dLSerum creatinine1.1 mg/dL0.7–1.3 mg/dLRandom blood sugar5.2 mmol/L4.0–6.0 mmol/LUrinalysis6–8 pus cells/HPF<5 pus cells/HPFViral serology initiallyHBsAg negative, HIV negative- Initial laboratory investigations. An upper GI endoscopy (UGIE) performed during this admission revealed grade III esophageal varices with hypertensive gastropathy features (Fig. 1). Based on these findings, a diagnosis of acute variceal hemorrhage secondary to portal hypertension was made, and the patient was conservatively managed with intravenous fluids, supportive medication, and one unit of whole blood transfusion, which resulted in his hemodynamic stability. Figure 1.Esophageal varices grade III (A—red arrow) with red spots (B—green arrow) and portal hypertensive gastropathy (C—white arrow). Esophageal varices grade III (A—red arrow) with red spots (B—green arrow) and portal hypertensive gastropathy (C—white arrow). The patient was scheduled for a follow-up endoscopy, which was performed 7 months later. During that period, the findings had changed, showing grade II–III esophageal varices and congestive gastropathy (Fig. 2). No active source of bleeding was observed during this procedure. Figure 2.Grade II-III esophageal varices (A—red arrow) with congestive gastropathy (B—white arrow). Grade II-III esophageal varices (A—red arrow) with congestive gastropathy (B—white arrow). Again, 1 week later, he was admitted due to the passage of black tarry stool and hematemesis. His blood pressure was still within normal limits at 110/70 mmHg during this examination, though he remained anemic on physical examination. There was no clinical evidence of jaundice, hepatomegaly, or splenomegaly on his examination. Laboratory work on this admission revealed hemoglobin of 7.2 g/dL, total bilirubin of 1.5 mg/dL, SGPT of 68 IU/L, and SGOT of 60 IU/L. Viral serology was HBeAg-negative, anti-HBs antibody-negative, and anti-HBc IgG-negative. Interestingly, HBsAg remained negative, but HBV DNA was positive, which established the diagnosis of OBI (Table 2). Serum alpha-fetoprotein was also negative. The patient received 1 unit of whole blood for anemia.Table 2Key clinical events.CategoryDetailsInitial UGIEGrade III esophageal varices with red spots and portal hypertensive gastropathy. No active bleeding after stabilization.Follow-up UGIE (7 months)Grade II–III esophageal varices with congestive gastropathy.Repeat Admission FindingsViral tests: HBeAg negative, anti-HBs antibody negative, anti-HBc IgG negative, HBV DNA positive (occult HBV infection confirmed). Serum alpha-fetoprotein (AFP) negative. Abdominal ultrasound: Normal liver size and architecture, no cirrhosis or focal lesions, no ascites, no hepatomegaly or splenomegaly.Subsequent UGIEPersistent medium-sized varices with red signs indicating high bleeding risk.Endoscopic InterventionsTwo EVL sessions were performed successfully without complications.Diagnostic AssessmentPortal hypertension is diagnosed by endoscopy. Occult HBV infection is identified by HBV DNA positivity despite negative serology and no cirrhosis on imaging.Treatment HistoryAcute management: intravenous fluids, hemodynamic stabilization, and blood transfusions. Initiation of a non-selective beta-blocker (propranolol). Two EVL sessions to control and prevent variceal rebleeding. Supportive care during acute hemorrhage ensured patient safety. Table 2Key clinical events.CategoryDetailsInitial UGIEGrade III esophageal varices with red spots and portal hypertensive gastropathy. No active bleeding after stabilization.Follow-up UGIE (7 months)Grade II–III esophageal varices with congestive gastropathy.Repeat Admission FindingsViral tests: HBeAg negative, anti-HBs antibody negative, anti-HBc IgG negative, HBV DNA positive (occult HBV infection confirmed). Serum alpha-fetoprotein (AFP) negative. Abdominal ultrasound: Normal liver size and architecture, no cirrhosis or focal lesions, no ascites, no hepatomegaly or splenomegaly.Subsequent UGIEPersistent medium-sized varices with red signs indicating high bleeding risk.Endoscopic InterventionsTwo EVL sessions were performed successfully without complications.Diagnostic AssessmentPortal hypertension is diagnosed by endoscopy. Occult HBV infection is identified by HBV DNA positivity despite negative serology and no cirrhosis on imaging.Treatment HistoryAcute management: intravenous fluids, hemodynamic stabilization, and blood transfusions. Initiation of a non-selective beta-blocker (propranolol). Two EVL sessions to control and prevent variceal rebleeding. Supportive care during acute hemorrhage ensured patient safety. Key clinical events. A repeat UGIE was performed. This revealed medium-sized esophageal varices with red signs, which were the reason for bleeding. He underwent his first session of endoscopic variceal ligation (EVL) (Fig. 3). The procedure was uneventful, and he was told to return for a follow-up evaluation after a month. Figure 3.The first session of endoscopic variceal ligation (EVL) shows band placement over esophageal varices (white arrow). The first session of endoscopic variceal ligation (EVL) shows band placement over esophageal varices (white arrow). During the follow-up evaluation, an abdominal ultrasound was performed. Surprisingly, this revealed a normal liver with preserved architecture and no focal lesions (Fig. 4). No ascites, hepatomegaly, or splenomegaly was observed. This was remarkable in the context of the patient’s history of chronic liver disease and portal hypertension. Figure 4.Normal liver with preserved architecture, without focal lesion on liver ultrasound (Red arrow). Normal liver with preserved architecture, without focal lesion on liver ultrasound (Red arrow). A repeat UGIE was performed a month later, which again demonstrated medium-sized esophageal varices with red signs, as noted in previous observations. A week later, the patient underwent a second session of EVL, which was performed successfully. He was advised upon discharge to return for follow-up visits regularly, undergo a repeat endoscopy in 6 months, and have an assessment for further EVL or sclerotherapy as dictated by follow-up findings. Follow-up and Outcomes The patient remained hemodynamically stable after EVL sessions, with no further bleeding episodes reported. Serial endoscopies showed stable varices, and liver function tests remained within normal limits, with no evidence of disease progression on imaging. Discussion OBI is a condition characterized by the presence of replication-competent HBV DNA in the liver tissue, while the surface antigen (HBsAg) remains undetectable in the blood. In some cases, small amounts of viral DNA may still be detectable in the serum. This form of infection is marked by a very low level of viral replication, with the covalently closed circular DNA (cccDNA) persisting in a latent or minimally active state within liver cells[6]. In patients with OBI, the presence of cccDNA within liver cells can result in minimal yet continuous viral transcription and replication, which may explain the absence of detectable HBsAg. The ongoing presence of viral DNA in these individuals can promote liver inflammation and fibrosis, particularly when accompanied by other contributing factors such as hepatitis C virus (HCV) co-infection or alcohol use. Although these changes might not be apparent through standard serological tests or imaging studies, they can still elevate portal pressure and lead to the development of varices[7,8]. This case is notable because the patient had repeated variceal bleeding and portal hypertension with normal liver architecture on ultrasound and negative standard hepatitis B markers, but positive HBV DNA, confirming OBI. This highlights the importance of HBV DNA testing in patients with unexplained portal hypertension and variceal bleeding. Portal hypertension is a serious consequence of liver disease that develops when various pathological changes lead to increased resistance to the flow of blood through the portal venous system into the liver. The main factor contributing to portal hypertension is the rise in intrahepatic vascular resistance, which occurs because of significant structural alterations, such as fibrosis and increased vascular tone within the liver’s microcirculation. As this condition advances, collateral vessel formation and arterial dilation increase, leading to greater blood flow within the portal system. Over time, a hyperdynamic circulatory state develops, marked by reduced mean arterial pressure, lower systemic vascular resistance, and elevated cardiac index. These changes contribute to the development of esophageal varices and increase the risk of life-threatening variceal bleeding[8]. While overt HBV infection is a major cause of cirrhosis, OBI is increasingly recognized as an underdiagnosed contributor to chronic liver injury and portal hypertension, despite negative HBsAg and other conventional serologic markers[2]. A systematic exclusion of alternative Non-Cirrhotic Portal Hypertension (NCPH) added value to the diagnosis of OBI in this patient. Pre-sinusoidal causes, such as portal vein thrombosis, schistosomiasis, and congenital hepatic fibrosis, were ruled out by Doppler ultrasound, which showed a patent portal vein, no splenomegaly, and no history of travel to endemic areas. Sinusoidal causes, including non-alcoholic steatohepatitis (NASH), alcoholic liver disease, other viral hepatitis (HCV, HDV negative), and infiltrative disorders like amyloidosis, were excluded via normal transaminases (except during acute bleeding episodes), no alcohol use, and lack of steatosis or fibrosis on imaging[9]. Post-sinusoidal obstructions, such as Budd-Chiari syndrome or sinusoidal obstruction syndrome, were ruled out by normal hepatic vein patency on ultrasound and the absence of hypercoagulable states. Conditions associated with idiopathic NCPH (INCPH), including immunodeficiencies (e.g., common variable immunodeficiency), connective tissue diseases, HIV, or toxin exposure (e.g., azathioprine, didanosine), lacked supporting history and serologies[9]. The absence of cirrhosis on imaging suggests early or subtle liver damage not detectable by ultrasonography, consistent with findings that portal hypertension may develop before overt cirrhosis is evident. EVL remains the standard of care for managing acute and recurrent variceal hemorrhage and was effective in this case[10]. However, antiviral therapy could be considered to suppress HBV replication and prevent disease progression, although the role of antivirals in OBI is not well established[3]. This case underscores the masked nature of OBI as a driver of portal hypertension and life-threatening hemorrhage, warranting heightened clinical suspicion, especially in patients without other identifiable etiologies. Early diagnosis and timely endoscopic intervention are critical to improving outcomes. Clinical implications OBI has potential for progressive fibrosis, HCC risk (up to 5-fold higher), and reactivation under immunosuppression, often missed by HBsAg screening[9]. WHO guidelines recommend HBV DNA testing by nucleic acid testing (NAT) in high-risk cryptogenic cases, particularly those with varices, to guide management. Long-term follow-up for fibrosis progression and HCC surveillance is warranted in occult HBV infection. Occult hepatitis B must be considered in patients with portal hypertension and variceal bleeding, especially when conventional HBV serology is negative. Early detection may facilitate timely therapeutic decisions, including antiviral therapy and endoscopic interventions, to reduce morbidity and mortality. Normal liver imaging does not exclude portal hypertension or underlying viral liver disease. Strengths and limitations Strengths Comprehensive clinical, endoscopic, and laboratory findings confirm the diagnosis, emphasizing the importance of HBV DNA testing in atypical portal hypertension and outlining effective management and follow-up outcomes. Limitations A single case report limits external validity. The lack of a liver biopsy prevents histologic confirmation of fibrosis or inflammation. No antiviral therapy was instituted, nor were long-term outcomes reported. Conclusions OBI is an important but underrecognized cause of portal hypertension and variceal hemorrhage. Diagnosis requires a high index of suspicion and molecular testing beyond standard serology. Appropriate endoscopic therapy and vigilant follow-up are critical. Further research on the management and prognosis of OBI-related portal hypertension is warranted.